Welcome to YHEC’s publication hub

Our latest research, all in one place. Browse our collection of journal articles, reports and conference proceedings to see how we’re contributing to HEOR research. Remember to: 

  • Filter by service, therapeutic area, or geography to narrow your results.
  • Search directly for keywords or specific titles to find what you need instantly.
Conference proceeding

The Burden of Operating Room Waste: How to Win-Win and Aid Decision Makers to Support Healthcare Sustainability

YHEC authors: Melissa Pegg
Publication date: September 2024
Conference: Healthcare Facilities Management, Birmingham
Type of conference proceeding: Podium
Report

[GID-HTE10041] Topical Antimicrobial Dressings for Infected Leg Ulcers in People 16 and Over: External Assessment Group Report

YHEC authors: Hayden Holmes, Lavinia Ferrante di Ruffano, Laura Kelly, Mary Edwards, Angel Varghese, Sarah Medland, Mick Arber, Emma Carr, Ben Hyde, Monica Garrett, Sam Woods
Publication date: August 2024
Publishers: National Insitute for Health and Care Excellence

Abstract

No abstract available.

Peer-reviewed publication

Literature Review and Meta-Analysis of Natalizumab Therapy for the Treatment of Highly Active Relapsing Remitting Multiple Sclerosis in the ‘Suboptimal Therapy’ Patient Population

YHEC authors: Mary Chappell, Alice Sanderson, Heather Davies, Deborah Watkins, Mick Arber, Rachael McCool
Publication date: August 2024
Journal: Journal of the Neurological Sciences

Abstract

BACKGROUND: Highly active (HA) relapsing remitting multiple sclerosis (RRMS) is associated with frequent relapses and high burden of disease/disability. Natalizumab is licensed for HA RRMS, including rapidly evolving severe (RES) (=2 relapses in previous year) and sub-optimally treated (SOT) (=1 relapse in previous year despite treatment) populations. However, there is limited RCT evidence in the SOT subpopulation.

OBJECTIVE: To review the non-RCT evidence for natalizumab in SOT HA RRMS.

METHODS: Databases were searched to January 2023 for non-randomised studies of natalizumab in HA RRMS. Studies in patients with =1 relapse during previous treatment were eligible for inclusion. Meta-analyses were conducted to compare natalizumab with platform and higher efficacy disease-modifying therapies, with sensitivity analysis restricted to studies of low risk of bias.

RESULTS: Included comparative studies (n = 16) showed natalizumab had lower relapse rates, disease activity and MRI (radiological) outcomes compared with platform and higher efficacy therapy. Case series (n = 11) showed natalizumab was associated with high rates of freedom from relapse and clinical/radiological disease activity and reductions in annualised relapse rate and disability progression.

CONCLUSIONS: Literature reviewed indicates that natalizumab is more effective than other included treatments for SOT patients. Findings were consistent with studies in the broad HA RRMS population, suggesting that natalizumab may have similar efficacy for SOT and RES HA RRMS.

Conference proceeding

Systematic Literature Review of the Clinical Efficacy and Safety of Treatments for Postpartum Depression

YHEC authors: Anita Fitzgerald, Lavinia Ferrante di Ruffano
Publication date: August 2024
Conference: International Marcé Society Conference, Barcelona
Type of conference proceeding: Poster
Peer-reviewed publication

The Economic Impact of Introducing RefluxStop for Refractory Gastroesophageal Reflux Disease on the Italian Healthcare System

YHEC authors: Sam Harper, Stuart Mealing
Publication date: August 2024
Journal: PharmacoEconomics

Abstract

INTRODUCTION: Gastroesophageal reflux disease (GERD) is a common ailment associated with troublesome symptoms. The standard of care in Italy involves initial treatment with proton pump inhibitor (PPI)-based medical management or laparoscopic Nissen fundoplication (LNF) for patients unwilling to continue or intolerant of long-term PPI therapy. RefluxStop is a novel medical device, intended for laparoscopic implantation, that has recently proven to be an efficacious and cost-effective treatment option for patients with GERD. This analysis aims to describe the short-term budget impact of introducing RefluxStop as a GERD treatment option within the Italian National Health Service (SSN).

METHODS: A model adherent to international best practice recommendations was developed to estimate the budget impact of introducing RefluxStop over a 5-year time horizon. Two scenarios were considered: one without RefluxStop (i.e., comprising PPI therapy, LNF, and magnetic sphincter augmentation using the LINX system); and one with RefluxStop (i.e., addition of RefluxStop to the three treatment options previously mentioned). Clinical benefits and costs associated with each intervention were included in the analysis.

RESULTS: Over 5 years, the introduction of RefluxStop resulted in avoidance of 95 surgical failures, 11 reoperations, and 64 endoscopic esophageal dilations. Introduction of RefluxStop resulted in an almost neutral impact on the existing budget with a 0.316% increase in the annual Italian SSN spending on GERD treatment.

CONCLUSION: Introduction of RefluxStop as a GERD treatment option in Italy is likely to be associated with substantial clinical benefits and a marginal budget impact.

Peer-reviewed publication

A Danish Healthcare-Focused Economic Evaluation of First-Line Cryoballoon Ablation Versus Antiarrhythmic Drug Therapy for the Treatment of Paroxysmal Atrial Fibrillation

YHEC authors: Joe Moss, Stuart Mealing, Daniela Afonso, Tom Bromilow
Publication date: July 2024
Journal: BMC Cardiovascular Disorders

Abstract

INTRODUCTION: Three randomised controlled trials (RCTs) have demonstrated that first-line cryoballoon pulmonary vein isolation decreases atrial tachycardia in patients with symptomatic paroxysmal atrial fibrillation (PAF) compared with antiarrhythmic drugs (AADs). The aim of this study was to develop a cost-effectiveness model (CEM) for first-line cryoablation compared with first-line AADs for the treatment of PAF. The model used a Danish healthcare perspective.

METHODS: Individual patient-level data from the Cryo-FIRST, STOP AF and EARLY-AF RCTs were used to parameterise the CEM. The model structure consisted of a hybrid decision tree (one-year time horizon) and a Markov model (40-year time horizon, with a three-month cycle length). Health-related quality of life was expressed in quality-adjusted life years (QALYs). Costs and benefits were discounted at 3% per year. Model outcomes were produced using probabilistic sensitivity analysis.

RESULTS: First-line cryoablation is dominant, meaning it results in lower costs (-€2,663) and more QALYs (0.18) when compared to first-line AADs. First-line cryoablation also has a 99.96% probability of being cost-effective, at a cost-effectiveness threshold of €23,200 per QALY gained. Regardless of initial treatment, patients were expected to receive ~ 1.2 ablation procedures over a lifetime horizon.

CONCLUSION: First-line cryoablation is both more effective and less costly (i.e. dominant), when compared with AADs for patients with symptomatic PAF in a Danish healthcare system.

Conference proceeding

Incorporating Environmental Sustainability into Healthcare Decision Making: A Parallel Evaluation of a Single-Use versus Reusable Health Technology

YHEC authors: Rebecca Naylor, Melissa Pegg
Publication date: July 2024
Conference: HSR UK, Oxford
Type of conference proceeding: Oral presentation

Abstract

BACKGROUND: Single use health technologies are known to be approximately 50% more environmentally harmful than their reusable equivalent [1-3]. This novel pilot study was undertaken for the Scottish Health Technologies Group (SHTG) and is the first UK published parallel assessment alongside a cost effectiveness evaluation [4]. The aim of this research was to use hybrid and innovative methodological approach to evaluate environmental impact, utilising established multidisciplinary methods, in conjunction with HTA principles.

METHODS: Through the application of environmental management principles and reporting, the Greenhouse Gas (GHG) Protocols [5], ISO14040 [6] and Publicly Available Specification (PAS) 2050 [7] were applied in combination with overarching HTA principles. An environmental life cycle assessment (LCA) of single use rhinolaryngoscopes was compared with a reusable equivalent. A hybrid approach was used to collect data to quantify carbon intensity including, process activity data, real world data and secondary data. Data were extrapolated to estimate national GHG emissions and waste volumes to support NHS sustainability targets. The carbon output per functional unit were categorised using thresholds based on PAS recommendations to strengthen support for the HTA decision making process. Sensitivity analyses were performed to overcome data issues. Further recommendations were made support NHS net zero targets, promoting the use of more sustainable health technologies along the healthcare pathway.

RESULTS: The carbon emissions of a single use flexible rhinolaryngoscope compared to its reusable equivalent was 6.03kgCO2e and 3.26kgCO2e respectively. The findings of the report are in line with research reporting similar carbon emissions and provide important methods for HTA. Data extrapolation (2264 procedures per annum) reveals the annual environmental impact of this technology, throughout NHS Scotland, to be 13,652kgCO2e and 7,381kgCO2e, for the single use and reusable devices, respectively. Raw material acquisition, the use of personal protective equipment and transportation were highlighted as carbon hotspots along the healthcare pathway. The estimated waste volumes are 12.58 tonnes and negligible volumes of clinical waste per annum for the single use versus reusable equivalent, respectively.

LIMITATIONS: A comparable LCA relies on a solid foundation of data. However, a high-level life cycle inventory based on good quality data was not possible for this parallel assessment, mainly attributed to the lack of access to primary data sources; influenced by a lack of regulation. Consequently, there was heavy reliance on secondary data and therefore the findings of this study may lack robustness and should be considered with caution.

IMPLICATIONS: The findings of this study support health technology environmental sustainability policy and framework development. This study recommends a hybrid methodological approach to evaluate environmental impact of health technologies. This approach supports product LCA [8] and carbon hotspot evaluation. This research also supports valuable data generation in a field nascent of research to support methodological development [9-11]. According to literature, this is the first parallel assessment as part of a HTA to be published [10]. Environmental outcomes used in the pilot study, align with government and NHS England net zero and waste reduction objectives [12]. This pilot study focuses on reporting GHG emissions. This is reasonable given that climate change and planetary health is determined largely by anthropogenic GHG emissions; fundamental for the stability of other environmental systems [13], and that national targets are focused on GHG emissions [12]. However, measuring GHG emissions and waste volumes only, can be considered a disadvantage, in that other important environmental impacts across other areas may be overlooked [1, 2, 14]. Therefore, future research should undertake a broader environmental assessment.

1 … 17 18 19 20 21 … 83